Structure-activity relationships of chiral selective norepinephrine reuptake inhibitors (sNRI) with increased oxidative stability

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 16, 2008, Pages 4491-4494

  Hudson, Sarah ^a   Kiankarimi, Mehrak ^a   Eccles, Wendy ^a   Dwight, Wesley ^a   Mostofi, Yalda S ^a   Genicot, Marc J ^a   Fleck, Beth A ^a   Gogas, Kathleen ^a   Aparicio, Anna ^a   Wang, Hua ^a   Wen, Jenny ^a   Wade, Warren S ^a  

^a NEUROCRINE BIOSCIENCES INC   (United States)

Author keywords

Norepinephrine; Serotonin

Indexed keywords

ATOMOXETINE; CYTOCHROME P450 2D6; HETEROCYCLIC COMPOUND; MONOAMINE; NORADRENALIN UPTAKE INHIBITOR;

AEROBIC METABOLISM; ARTICLE; CELL STRAIN HEK293; CHIRALITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; LIVER MICROSOME; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ADRENERGIC UPTAKE INHIBITORS; CHEMISTRY, PHARMACEUTICAL; CYTOCHROME P-450 CYP2D6; DRUG DESIGN; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, CHEMICAL; MOLECULAR CONFORMATION; NOREPINEPHRINE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; OXYGEN; PROPYLAMINES; STRUCTURE-ACTIVITY RELATIONSHIP; SYMPORTERS;

EID: 48649097476     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.07.049     Document Type: Article

References (19)

1. Jann M.W., and Slade J.H. Pharmacotherapy 27 (2007) 1571
2. Babu R.P.K., and Maiti S.N. Heterocycles 69 (2006) 539
3. Zhou J. Drugs Future 29 (2004) 1235
4. Wernicke J.F., Iyengar S., and Ferrer-Garcia M.D. Curr. Drug Ther. 2 (2007) 161
5. Wu D., Pontillo J., Ching B., Hudson S., Gao Y., Fleck B.A., Gogas K., and Wade W.S. Bioorg. Med. Chem. Lett. 18 (2008) 4224
6. Hudson S., Kiankarimi M., Eccles W., Mostofi Y.S., Genicot M.J., Dwight W., Fleck B.A., Gogas K., and Wade W.S. Bioorg. Med. Chem. Lett. 18 (2008) 10.1016/j.bmcl.2008.07.050
7. Witherington J., Bordas V., Gaiba A., Naylor A., Rawlings A.D., Slingsby B.P., Smith D.G., Takle A.K., and Ward R.W. Bioorg. Med. Chem. Lett. 13 (2003) 3059
8. Meyer E.A., Furler M., Diederich F., Brenk R., and Klebe G. Helv. Chim. Acta 87 (2004) 1333
9. 3, Z = 4, T = 208 K. R(F) = 6.30% based on 4918 independent reflections.
10. Kiankarimi, M.; Hudson, S.; Dwight, W. J.; Wade, W.S. Preparation of benzofuranylmethylamines, chromanylmethylamines, and thiochromanylmethylamines as monoamine reuptake inhibitors, US 2006252818.
11. Recombinant CYP2D6 or CYP3A4 was incubated with a marker substrate and a NADPH-generating system for 30 min at 37 °C in the presence of varying concentrations of test compound. CYP3A4 activity was quantitated from the cleavage of substrate BFC to its fluorescent product 7-HFC. Ketoconazole was used as a positive control. CYP2D6 activity was quantitated from the cleavage of AMMC to its fluorescent product AHMC. Quinidine was used as positive control.
12. Test compounds were incubated at 1 μM concentration in the presence of pooled human liver microsomes (0.5 mg/mL; n > 10; mixed gender) in the presence of an NADPH-generating system. The rate of disappearance of the parent compound was quantitated by LC/MS/MS at five time points over 60 min and the measured rate scaled to human body mass.
13. Cahn R.S., Ingold C., and Prelog V. Angew. Chem., Int. Ed. Engl. 5 (1966) 385
14. Sauer J.-M., Ring B.J., and Witcher J.W. Clin. Pharmacokinet. 44 (2005) 571
15. Molecule structures were imported into the Molecular Operating Environment (MOE) software version 2007.09 and subjected to Stochastic Conformation Search using the MMFF94x force field with GBSA implicit solvation. Low energy conformations within 1.5 kcal/mol from the minimum that were most consistent with the known solid-state X-ray crystal structures were taken forward and aligned using the Flexible Alignment module using default field similarity terms except hydrogen-bonding terms were scaled down to 0.5. The best scoring alignment most consistent with known structure-activity patterns for NET:SERT selectivity was retained.
16. Ereshefsky L., Riesenman C., and Lam Y.W. J. Clin. Psychiatry 57 (1996) 17
17. Preskorn S.H., Shah R., Neff M., Golbeck A.L., and Choi J. J. Psychiatr. Pract. 13 (2007) 5
18. Skinner M.H., Kuan H.-Y., Pan A., Sathirakul K., Knadler M.P., Gonzales C.R., Yeo K.P., Reddy S., Lim M., Ayan-Oshodi M., and Wise S.D. Clin. Pharmacol. Ther. 73 (2003) 170
19. Calculated log Ps were determined using ACD/Log P DB, version 9.02, Advanced Chemistry Development, Inc., Toronto, ON, Canada, www.acdlabs.com, 2005. Calculated and measured values for atomoxetine, 3-I and 4-I were the same within experimental error.